Specifically, gp130 signaling becomes rate limiting for the growth of gastrointestinal tumors arising from oncogenic driver mutations in Apc. In the present study, we investigate whether pharmacological targeting of gp130 with the selective estrogen receptor modulator bazedoxifene, clinically approved for the treatment of osteoporosis, is an effective treatment in preclinical models of gastric and colon cancers. Here, IL6ST is linked to malignant colon neoplasm.